# Intellia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intellia-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.intelliatx.com
- Total disclosed funding: $85M
- Latest round: Series B (Sep 1, 2015)
- Investors on record: 8

## About

Intellia Therapeutics, Inc. focuses on pioneering genome editing therapies using CRISPR technology to develop groundbreaking treatments for severe genetic diseases, enhancing patient outcomes and providing innovative healthcare solutions.Intellia Therapeutics, Inc. is engaged in the development of CRISPR gene editing therapies. The company was founded in 2014 and is headquartered in Cambridge, US. The founders are Erik Sontheimer and Rodolphe Barrangou, with Nessan Bermingham serving as CEO. Intellia has undergone significant financing rounds, most recently raising USD 600 mn in a Private Placement in June 2021. The total amount raised by the company to date is USD 600 mn, with 8 deals completed as of November 1, 2017.Intellia Therapeutics specializes in developing innovative genome editing treatments aimed at addressing severe diseases through its core product offerings, which include Lonvoguran Ziclumeran (lonvo-z) for patients with Hereditary Angioedema (HAE). These treatments leverage CRISPR technology to create potentially curative solutions, focusing on enhancing patient outcomes by targeting the root causes of genetic disorders. The company's offerings are designed to empower patients by providing confidence in their treatment options, enabling them to make informed decisions regarding their health. Intellia primarily serves patients suffering from rare genetic diseases, healthcare professionals, and researchers across multiple geographical markets, including North America and Europe.Intellia Therapeutics generates revenue through various structured transactions that align with its focus on developing and commercializing its genetic therapies. For the most recent year, 2024, Intellia reported revenues of USD 57.88 mn and an EBITDA of USD -541.80 mn. Revenue streams may include partnerships with healthcare institutions for clinical trials and collaborations with pharmaceutical companies on drug development, particularly involving flagship products like Lonvoguran Ziclumeran. These partnerships typically involve agreements that facilitate access to their proprietary research and development capabilities while allowing clients, such as healthcare providers and research organizations, to utilize their innovative therapies. The company may also engage in direct-to-consumer models for certain products as they progress toward commercialization, further diversifying its revenue framework within the biopharmaceutical landscape.Intellia Therapeutics plans to leverage its recent funding of USD 600 mn to accelerate the development of its gene editing pipeline and to enhance its platforms for gene editing and delivery, while also strengthening its intellectual property portfolio. The company is focusing on expanding its offerings for Lonvoguran Ziclumeran and aims to introduce new products targeting other genetic disorders in the coming years. Furthermore, Intellia is exploring opportunities to enter new geographic markets, particularly targeting Europe and Asia by 2025, to broaden its reach and impact.

## Funding rounds

- Series B, Sep 1, 2015, $70M — Atlas Venture, OrbiMed Advisors, Novartis Venture Fund, Fidelity Investments, Janus Henderson Investors, Foresite Capital, Sectoral Asset Management, EcoR1 Capital
- Series A, Nov 18, 2014, $15M — Atlas Venture, Novartis Venture Fund

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Janus Henderson Investors — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B